Literature DB >> 11106214

Up-regulation of circulating adhesion molecules in bronchiectasis.

L Zheng1, G Tipoe, W K Lam, R Y Leung, J C Ho, I H Shum, G C Ooi, M S Ip, K W Tsang.   

Abstract

Adhesion molecules are expressed on the surface of endothelial cells and leukocytes and are responsible for mediating the migration of intravascular leukocytes into inflamed tissue. Intensive recruitment of neutrophils into the airways occurs in bronchiectasis, although little is known about the role of adhesion molecules in this process. The authors, therefore, determined serum levels of E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular adhesion molecule (VCAM)-1 in stable bronchiectasis patients (n=37) and healthy control subjects (n=17), and evaluated their relationship with clinical markers of disease severity in bronchiectasis. Serum levels of E-selectin, ICAM-1 and VCAM-1 in bronchiectasis patients were significantly higher than those in control subjects (p=0.02, <0.0001 and 0.0002 respectively). Both E-selectin and ICAM-1 levels were inversely related to forced expiratory volume in one second (FEV1)% predicted (r=-0.57, p<0.001; and r=-0.53, p=0.001 respectively), and FVC% predicted (r=-0.52, p=0.002; and r=-0.46, p=0.005). This was not the case for VCAM-1 levels. There was a correlation between serum ICAM-1 levels and 24 h sputum volume (r=0.34, p= 0.04). Serum E-selectin and ICAM-1, but not VCAM-1, levels showed correlation with the number of lung lobes affected by bronchiectasis (r=0.35, p=0.04 and r=0.34, p=0.04 respectively). These original observations strongly suggest that E-selectin, intercellular adhesion molecule-1 and Vascular adhesion molecule-1 could play a significant role in the pathogenesis of bronchiectasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106214     DOI: 10.1034/j.1399-3003.2000.16d21.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Children with chronic suppurative lung disease have a reduced capacity to synthesize interferon-gamma in vitro in response to non-typeable Haemophilus influenzae.

Authors:  Susan J Pizzutto; Stephanie T Yerkovich; John W Upham; Belinda J Hales; Wayne R Thomas; Anne B Chang
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

2.  The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis.

Authors:  Hamdan Al-Jahdali; Abdullah Alshimemeri; Abdullah Mobeireek; Amr S Albanna; Nehad N Al Shirawi; Siraj Wali; Khaled Alkattan; Abdulrahman A Alrajhi; Khalid Mobaireek; Hassan S Alorainy; Mohamed S Al-Hajjaj; Anne B Chang; Stefano Aliberti
Journal:  Ann Thorac Med       Date:  2017 Jul-Sep       Impact factor: 2.219

3.  Clinical impact of cardiovascular disease on patients with bronchiectasis.

Authors:  Shanshan Chen; Aimin Qiu; Zhang Tao; Hailin Zhang
Journal:  BMC Pulm Med       Date:  2020-04-23       Impact factor: 3.317

Review 4.  The pathophysiology of bronchiectasis.

Authors:  Paul T King
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29

5.  The immune response and its therapeutic modulation in bronchiectasis.

Authors:  Massoud Daheshia; James D Prahl; Jacob J Carmichael; John S Parrish; Gilbert Seda
Journal:  Pulm Med       Date:  2012-10-10

Review 6.  The Role of the Immune Response in the Pathogenesis of Bronchiectasis.

Authors:  Paul T King
Journal:  Biomed Res Int       Date:  2018-03-18       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.